Huskisson E C, Scott J
Eur J Rheumatol Inflamm. 1981;4(2):212-8.
A double-blind study showed that four weekly intra-articular injections of 4 mg orgotein were superior to four weekly injections of saline in reducing pain, the duration of morning stiffness and effusions in patients with osteoarthritis. Forty patients with active osteoarthritis of the knee joint were studied. Patients without demonstrable effusion in the joint to be injected were excluded from the study. They were assigned at random to two treatment groups. The treatments appeared identical and the trial was therefore double-blind. The groups were well matched for age, sex, duration of disease and most other measurements made at the start of the study. Orgotein was safe and well tolerated. It caused only slightly more adverse reactions than placebo. Patients receiving orgotein showed no greater radiological deterioration than those receiving placebo.
一项双盲研究表明,对于骨关节炎患者,每周一次关节内注射4毫克奥古蛋白,连续注射四周,在减轻疼痛、晨僵持续时间和积液方面,优于每周一次注射生理盐水。该研究纳入了40名膝关节活动性骨关节炎患者。关节内无可证实积液的患者被排除在研究之外。他们被随机分为两个治疗组。两种治疗方法外观相同,因此该试验为双盲试验。两组在年龄、性别、病程以及研究开始时进行的大多数其他测量指标方面匹配良好。奥古蛋白安全且耐受性良好。与安慰剂相比,其引起的不良反应仅略多一些。接受奥古蛋白治疗的患者与接受安慰剂治疗的患者相比,影像学恶化程度并无更大差异。